Introduction
============

Chronic obstructive pulmonary disease (COPD) is characterized by poor reversible airflow limitation caused by varying combinations of bronchial airway disease and lung parenchymal emphysema.[@b1-copd-13-1691] The identification of blood biomarkers, particularly for emphysema, which could assess this heterogeneity may help to manage and treat patients with COPD.[@b1-copd-13-1691] The analysis of peripheral blood samples is considered a valid method for monitoring inflammatory biomarkers,[@b2-copd-13-1691] in addition to being easily available.

Smoking induces a significant increase of monocyte chemotactic protein (MCP)-1 levels in the bronchoalveolar lavage (BAL) fluid of both healthy smokers[@b3-copd-13-1691] and patients with chronic bronchitis,[@b4-copd-13-1691] and COPD patients show higher plasma MCP-1 levels compared with healthy controls.[@b5-copd-13-1691] However, MCP-1 plasma levels have not been analyzed according to the different COPD phenotypes. Both interleukin (IL)-1α and IL-1β are proinflammatory cytokines produced mainly by monocytes, macrophages, and fibroblasts.[@b6-copd-13-1691],[@b7-copd-13-1691] There are increased levels of IL-1β in serum, sputum, and BAL in patients with stable COPD.[@b8-copd-13-1691],[@b9-copd-13-1691] There is evidence that inflammation in COPD is characterized by an increase in the levels of IL-6, IL-8, and tumor necrosis factor (TNF)-α in the peripheral blood.[@b10-copd-13-1691] IL-8 is a chemotactic factor for neutrophils. Levels increase in induced sputum of COPD patients as the number of exacerbations increases.[@b11-copd-13-1691] The proinflammatory cytokine IL-6 may play an important role in the progression of COPD severity,[@b12-copd-13-1691] and increased serum levels of IL-6 during COPD exacerbations have been described.[@b13-copd-13-1691] However, comorbidities may influence the IL-6 plasma level increase.[@b14-copd-13-1691] TNF-α is an important chemotactic protein for neutrophils, and its increase in the blood of COPD patients may induce an increased expression of adhesion molecules. Increased circulating TNF-α might also be the cause of skeletal muscle cell apoptosis (muscle cachexia) in COPD patients.[@b15-copd-13-1691],[@b16-copd-13-1691] IL-2 is necessary for the differentiation and expansion of T lymphocytes. Its serum levels were higher in patients with stable disease compared with patients with progressive COPD.[@b17-copd-13-1691] IL-4, a pleiotropic cytokine, produced by activated T cells, can facilitate the differentiation of both mucus-secreting tissue[@b18-copd-13-1691],[@b19-copd-13-1691] and B lymphocytes.[@b20-copd-13-1691] Interferon (IFN)-γ is produced by Th1 lymphocytes and is an essential component of the host immune responses to pathogens.[@b21-copd-13-1691] All COPD exacerbations are characterized by increased plasma levels of vascular endothelial growth factor (VEGF), which is a signal protein that stimulates vasculogenesis and angiogenesis. Increased plasma levels of IL-10, an anti-inflammatory cytokine, are found when COPD exacerbations are induced by virus.[@b22-copd-13-1691] Epidermal growth factor (EGF) stimulates human airway smooth muscle proliferation.[@b23-copd-13-1691] An increased EGF expression is reported in the epithelium and submucosal cells of patients with chronic bronchitis.[@b24-copd-13-1691]

Among the oxidant and antioxidant markers, the super-oxide dismutase (SOD)-1 family contains enzymes that catalyze the dismutation (or partitioning) of the superoxide (O~2~^−^) radical into either ordinary molecular oxygen (O~2~) or hydrogen peroxide (H~2~O~2~). Glutathione peroxidase (GPx) reduces lipid hydroperoxides to their corresponding alcohols and reduces free H~2~O~2~ to water. An increase in GPx and SOD activities has been found during exacerbations of COPD compared with stable disease.[@b25-copd-13-1691] In addition, there are F2-isoprostanes (F2-IsoPs), which are prostaglandin-like compounds formed by the free radical-mediated oxidation of arachidonic acid.[@b26-copd-13-1691] They are a fundamental marker for measuring oxidative stress in the body. F2-IsoPs also have potent biological effects associated with inflammation and therefore may mediate chronic disease initiation and progression. In particular, 8-iso prostaglandin F2 (PGF2),[@b27-copd-13-1691] an isomer of the PGF2 family (F2-IsoPs) also known as iPF2α-III, is a stimulating factor for pulmonary vascular and bronchial smooth muscle contraction.[@b28-copd-13-1691],[@b29-copd-13-1691] This suggests that this isoprostane may be a local marker of airway inflammation caused by oxidant injury. Again, a comparison of these oxidant and antioxidant markers between different phenotypes of COPD has not yet been performed.

The aim of this study was, therefore, to analyze some relevant inflammatory, oxidant, and antioxidant molecules present in different phenotypes of COPD patients showing prevalent airway disease versus prevalent emphysema.

Patients and methods
====================

Subjects
--------

All COPD and healthy control subjects included in this study were recruited from the Respiratory Medicine Unit of Istituti Clinici Scientifici Maugeri (Pavia, Italy). In COPD patients, the severity of the airflow obstruction was staged using the current Global Initiative for Chronic Obstructive Lung Disease criteria.[@b1-copd-13-1691] All former smokers had stopped smoking for at least 1 year prior to the study. The phenotypic attribution of each patient (prevalent airway disease versus prevalent emphysema) was based on clinical and instrumental data.[@b30-copd-13-1691],[@b31-copd-13-1691] According to this model, a score \>0.56 corresponded to the emphysema phenotype and \<0.56 corresponded to the prevalent airway disease phenotype. The group of patients with prevalent airway disease also suffered from chronic bronchitis. Chronic bronchitis was defined by the presence of cough and sputum production for at least 3 months in each of the 2 years prior to enrollment.[@b1-copd-13-1691] By definition, chronic bronchitis was not present in the group of COPD patients with prevalent emphysema. Control smokers (CSs) and control nonsmokers (CNSs) were recruited as volunteers. None of the patients were treated with theophylline, roflumilast, antibiotics, antioxidants, mucolytics, and/or glucocorticoids in the month prior to the collection of blood samples. All the patients were in a stable phase of the disease and had been free from any episode of exacerbation for at least 3 months. They were all on regular treatment with bronchodilators according to the prescription of the referring physician. [Table 1](#t1-copd-13-1691){ref-type="table"} summarizes the clinical details and functional data of the subjects.

### Ethical approval

Written informed consent was obtained from each participant prior to the study. The study was carried out in conformity with the 1975 Declaration of Helsinki, according to the local ethics committee guidelines, and it was approved by the Ethics Committee of the Istituti Clinici Scientifici Maugeri of Pavia (formerly, Fondazione Salvatore Maugeri, Istituto di Ricovero e Cura a Carattere Scientifico \[IRCCS\]; ethical committee number: 966).

Lung function tests and volumes
-------------------------------

Pulmonary function tests were performed as previously described[@b32-copd-13-1691] according to the guideline recommendations.[@b33-copd-13-1691] Pulmonary function tests included measurements of forced expiratory volume in 1 second (FEV~1~; L), FEV~1~%, FEV~1~/forced vital capacity (FVC; %), residual volume (RV), RV%, diffusing capacity of the lungs for carbon monoxide (DLCO), DLCO%, and the number of exacerbations/year under baseline conditions in all the subjects examined (V6200 Autobox Pulmonary Function Laboratory; SensorMedics, Yorba Linda, CA, USA; [Table 1](#t1-copd-13-1691){ref-type="table"}).

Blood/serum collection and analysis
-----------------------------------

Blood samples were collected in Vacutainer^®^ tubes (Becton Dickinson, Plymouth, UK) within 1 week after the diagnosis and spirometry evaluations. For serum preparation, venous blood was immediately centrifuged at 3,000 *g* for 15 minutes at 4°C. Serum was separated and stored in aliquots at −20°C until analysis.

Measurement of blood biomarkers
-------------------------------

### Serum cytokines and growth factors

The following cytokines and growth factors were determined: IL-1α, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, TNF-α, INF-γ, EGF, MCP-1, and VEGF. All these analyses were included in a single panel analyzed and quantified with Evidence Investigator, a high-throughput automated biochip immunoassay system (Randox Laboratories, Crumlin, UK). The biochip used consisted of a 9×9 mm substrate on which discrete test regions have been constructed. The binding ligands (antibodies) were attached to predefined sites on the chemically modified surface of the biochip. After the enzyme-linked immunosorbent assay procedure, each spot is imaged to capture the chemiluminescent signals generated at them on the array. The light signal is captured by a charge-coupled device camera as part of an imaging station and converted by image-processing software to provide results compared with calibration curves for each location on the biochip. The use of this protein array technology[@b34-copd-13-1691] has advantages over conventional assay methods that include simultaneous detection of multiple analyses from a minute plasma sample within a single assay.

### Blood antioxidant enzymes -- GPx1 and SOD1

The quantitative determination of GPx1 in whole blood was performed using a commercial immunochemical kit (RANSEL; Randox Laboratories). Briefly, the heparinized whole blood was diluted with 1 mL of diluting agent and incubated for 5 minutes. After incubation, 1 mL of hemoglobin reagent (cyanide) was added in order to avoid falsely elevated results due to the presence of endogenous peroxidases. Finally, the samples were assayed within 20 minutes using an automated analyzer (BT2000; Biotecnica Instruments, Limena, Italy). The quantitative determination of SOD1 in whole blood was performed using a commercial immunochemical kit (RANSOD; Randox Laboratories). Briefly, 0.5 mL of heparinized whole blood samples was centrifuged for 10 minutes at 3,000 rpm in order to carefully wash the erythrocytes. Then, the erythrocytes were washed four times with 0.9% NaCl solution and centrifuged for 10 minutes at 3,000 rpm after each wash. Subsequently, the erythrocytes were made up to 2.0 mL with cold redistilled water, mixed, and left to stand at +4°C for 15 minutes. Finally, the lysate was diluted with sample diluent and assayed immediately using an automated analyzer (BT2000; Biotecnica Instruments) according to the manufacturer's instructions.

### Plasma oxidative stress markers -- free F2-IsoPs

Blood was collected in heparinized tubes, and then blood samples were centrifuged at 2,400 *g* for 15 minutes at 4°C; the platelet-poor plasma was saved, and the buffy coat was removed by aspiration. Plasma samples were stored at −20°C until analyzed. Free F2-IsoPs were determined by gas chromatography/negative-ion chemical ionization tandem mass spectrometry (GC/NICI-MS/MS) in samples, as described by Signorini et al.[@b35-copd-13-1691],[@b36-copd-13-1691] In previous studies,[@b35-copd-13-1691]--[@b39-copd-13-1691] GC/NICI-MS/MS has proved to be a reliable procedure (in terms of specificity, repeatability, and accuracy) to assess F2-IsoPs as an indicator of free radical-induced lipid peroxidation. For plasma-free F2-IsoPs determination, butylated hydroxytoluene (90 μM) was added to the plasma as an antioxidant. An aliquot of plasma (1 mL) was spiked with tetradeuterated PGF2α (PGF2α-d4. 500 pg in 50 μL of ethanol; Cayman, Ann Arbor, MI, USA), as an internal standard. After acidification, by the addition of 2 mL of acidified water (pH =3), the extraction and purification procedure was carried out. It consisted of two solid-phase separation steps: an octadecylsilane (C18) cartridge followed by an aminopropyl (NH~2~) cartridge (Waters, Milford, MA, USA).[@b35-copd-13-1691] A derivatization step followed the solid-phase extraction. The carboxylic group was derived as the pentafluorobenzyl ester, whereas the hydroxyl groups were converted to trimethylsilyl ethers. In the GC/NICI-MS/MS analysis, the measured ions were the product ions at m/z of 299 and 303 derived from the \[M−181\]-precursor ions (m/z =569 and m/z =573) produced from 15-F2t-IsoPs, the most represented F2-IsoP isomer, and the tetradeuterated derivative of the PGF2α-d4, respectively.[@b35-copd-13-1691] Plasma-free F2-IsoPs were expressed as picograms per milliliter. The calibration curve correlations were adequate (r[@b2-copd-13-1691]=0.994); accuracy was 97.8%, and the variability coefficient was 2.5. The minimum detection limit was 5 pg/mL.

Statistical analysis
--------------------

Continuous data were expressed as mean ± standard deviation (SD). Biomarkers were expressed as median (range). Analysis of variance (ANOVA) and unpaired *t*-tests were applied for functional data. The Kruskal--Wallis test followed by Mann--Whitney *U* tests was applied for nonparametric parameters to compare all groups; *p*-values \<0.05 were considered as significant. All calculations were performed using the StatView^®^ (1992--1998 Version 5.0.1; SAS Institute Inc., Cary, NC, USA).

Results
=======

Clinical characteristics of subjects
------------------------------------

We studied blood serum biomarkers from 72 subjects: 45 with stable COPD, 9 CSs with normal lung function, and 18 nonsmokers with normal lung function ([Table 1](#t1-copd-13-1691){ref-type="table"}). COPD patients were divided into two groups by phenotype: COPD patients with prevalent airway disease (COPD-B group; n=23) and COPD patients with prevalent emphysema (COPD-E group; n=22) as stated in the "Methods" section, following cutoff values previously defined.[@b30-copd-13-1691] The smoking history did not differ significantly between the three smoking groups. COPD-B and COPD-E groups had similar age (mean ± SD: 73.78±5.87 and 71.77±5.56, respectively), and both differed from CSs (54.85±8.29, *p*\<0.01) and CNSs (49.28±7.56, *p*\<0.01). Values of FEV~1~, RVs (L and %), and FEV~1~/FVC (%) in each COPD group differed significantly from both control groups (healthy smokers and healthy nonsmokers). No significant differences were observed for functional parameters (FEV~1~, FEV~1~/FVC (%), RV, and DLCO), 6-minute walking test (6MWD), or numbers of exacerbations/year between the two COPD groups (B and E; [Table 1](#t1-copd-13-1691){ref-type="table"}).

Cytokines, growth factors, antioxidant enzymes, and oxidative stress markers in the blood
-----------------------------------------------------------------------------------------

Serum levels of IL-1β, IL-2, IL-4, IL-10, TNF-α, VEGF, and GPx1 did not differ significantly in the four groups ([Table 2](#t2-copd-13-1691){ref-type="table"}). IL-1α was significantly lower in COPD-B (*p*=0.0119), COPD-E (*p*=0.0408), and CNSs (*p*=0.0064) compared with CSs ([Tables 1](#t1-copd-13-1691){ref-type="table"} and [2](#t2-copd-13-1691){ref-type="table"}). IL-6 levels were significantly higher in COPD-B (*p*\<0.0001), COPD-E (*p*\<0.0001), and CSs (*p*=0.0064) compared with CNSs ([Tables 1](#t1-copd-13-1691){ref-type="table"} and [2](#t2-copd-13-1691){ref-type="table"}; [Figure 1A](#f1-copd-13-1691){ref-type="fig"}). IL-8 was significantly higher in COPD-B (*p*=0.0292) and COPD-E (*p*=0.0047) compared with CNSs ([Tables 1](#t1-copd-13-1691){ref-type="table"} and [2](#t2-copd-13-1691){ref-type="table"}; [Figure 1B](#f1-copd-13-1691){ref-type="fig"}). IFN-γ levels were significantly higher in CSs (*p*=0.0206) compared with CNSs ([Tables 1](#t1-copd-13-1691){ref-type="table"} and [2](#t2-copd-13-1691){ref-type="table"}). EGF levels were significantly higher in COPD-B (*p*=0.0459) and COPD-E (*p*=0.0036) than in CNSs ([Tables 1](#t1-copd-13-1691){ref-type="table"} and [2](#t2-copd-13-1691){ref-type="table"}; [Figure 1C](#f1-copd-13-1691){ref-type="fig"}). Interestingly, MCP-1 levels were significantly increased only in COPD-E compared with CSs and CNSs (*p*=0.0453 and 0.0023, respectively; [Tables 1](#t1-copd-13-1691){ref-type="table"} and [2](#t2-copd-13-1691){ref-type="table"}; [Figure 1D](#f1-copd-13-1691){ref-type="fig"}). SOD1 levels were significantly lower in COPD-B (*p*=0.0121) and COPD-E (*p*=0.0122) compared with CNSs ([Tables 2](#t2-copd-13-1691){ref-type="table"} and [3](#t3-copd-13-1691){ref-type="table"}; [Figure 1E](#f1-copd-13-1691){ref-type="fig"}). F2-IsoPs levels were significantly increased in COPD-B (*p*=0.0081 and \<0.0001, respectively) and COPD-E (*p*=0.0385 and \<0.0001, respectively) compared with both CSs and CNSs; CSs (*p*=0.0122) also showed increased F2-IsoPs levels compared with CNSs ([Tables 2](#t2-copd-13-1691){ref-type="table"} and [3](#t3-copd-13-1691){ref-type="table"}; [Figure 1F](#f1-copd-13-1691){ref-type="fig"}).

Correlations between oxidative stress markers and markers of inflammation or functional parameters
--------------------------------------------------------------------------------------------------

In the overall study population (patients and control subjects), the levels of F2-IsoPs oxidant marker correlated signifi-cantly and positively with the levels of circulating MCP-1 (R=0.30, *p*=0.014), IL-2 (R=0.33, *p*=0.008), IL-1β (R=0.34, *p*=0.005), IFN-γ (R=0.48, *p*=0.0001), and TNF-α (R=0.44, *p*=0.0004; [Figure 2A--E](#f2-copd-13-1691){ref-type="fig"}, respectively). Interestingly, F2-IsoPs levels also correlated inversely with SOD1 levels in the blood (R=−0.41, *p*=0.0001; [Figure 2F](#f2-copd-13-1691){ref-type="fig"}). Considering the COPD patients alone (B+E), F2-IsoPs levels in the blood correlated significantly and positively with IFN-γ levels (R=0.70, *p*\<0.0001), TNF-α (R=0.39, *p*=0.015), and IL-2 (R=0.49, *p*=0.002; [Figure 3A--C](#f3-copd-13-1691){ref-type="fig"}, respectively). All the R and *p*-values were maintained after exclusion of the outlier case: [Figure 2D](#f2-copd-13-1691){ref-type="fig"}, R=0.459, *p*=0.0003; [Figure 2E](#f2-copd-13-1691){ref-type="fig"}, R=0.413, *p*=0.0010; [Figure 2F](#f2-copd-13-1691){ref-type="fig"}, R=−0.394, *p*=0.0019; [Figure 3A](#f3-copd-13-1691){ref-type="fig"}, R=0.679, *p*\<0.0001; [Figure 3B](#f3-copd-13-1691){ref-type="fig"}, R=0.344, *p*=0.0338. No other significant correlations were observed between blood--blood biomarkers or blood versus functional data.

Discussion
==========

We have shown in this study that there is an increase in the oxidative stress marker F2-IsoPs and that there is a decrease in the antioxidant SOD1 in the blood of COPD patients, including those with prevalent airway disease and those with prevalent emphysema, compared with CNSs. A parallel increase in the inflammatory IL-6 and IL-8 and an increase in the remodeling marker EGF were also observed in these patients. MCP-1 selectively increased in the subgroup of patients with prevalent emphysema when compared to CNSs. In COPD patients, F2-IsoPs correlated positively with selected inflammatory markers.

Previous studies have shown higher plasma MCP-1 levels in COPD patients compared with healthy controls[@b4-copd-13-1691] and greater concentrations of inflammatory cells together with higher levels of IL-1β, IL-6, IL-8, and MCP-1 in smokers compared with nonsmokers.[@b2-copd-13-1691] However, these studies are only partially comparable with ours since we studied MCP-1 blood levels and inflammatory cytokines in two different phenotypes of COPD and compared them with both CSs and CNSs. Furthermore, 69% of our COPD patients were ex-smokers (quit smoking since at least 1 year). Interestingly, as an extension of a previous study,[@b4-copd-13-1691] we observed that the MCP-1 level in the blood was significantly increased in the subgroup of COPD patients with prevalent emphysema, suggesting a potential role for this molecule underlying the lung alterations related to this phenotype of COPD. In line with this notion, increased inflammation was reported in the lung parenchyma and alveolar spaces of patients with severe emphysema compared with patients with milder forms of disease.[@b40-copd-13-1691] However, we could not evaluate the role played by smoking habit in relation to blood biomarkers expression in our patients because of the lack of recent smoking exposure of the majority of our COPD patients (69% of patients equally distributed between B and E groups were ex-smokers since 1 year).

In blood samples, SOD1 levels have been found to be higher in lung cancer (LC)--COPD patients compared with LC patients alone or control subjects;[@b41-copd-13-1691] conversely, no significant changes in SOD1 genotype frequencies were found between COPD patients and CSs.[@b42-copd-13-1691] Exhaled 8-isoprostane concentrations were increased in COPD patients compared with healthy smokers and healthy nonsmokers,[@b43-copd-13-1691] and F2-IsoPs were considered central in the pathogenesis of COPD.[@b44-copd-13-1691] We observed a clear imbalance between blood F2-IsoPs and SOD1 in both groups of COPD patients (B and E), showing an increase in the oxidant marker, F2-IsoPs, and a decrease in SOD1 compared with CNSs. This finding seems to apply to all COPD patients irrespective of the degree of prevalent airway disease or lung emphysema. Interestingly, the oxidant molecule, F2-IsoPs, was positively correlated with the inflammatory markers of systemic inflammation (MCP-1, IL-2, IL-1β, IFN-γ, and TNF-α) and inversely correlated with SOD1 blood levels in all subjects, reinforcing the notion of a potential relationship between oxidant burden increase and related inflammation, on the one side, and decreased lung protection, on the other.

The blood glutathione peroxidase activity has been reported to be decreased in COPD patients compared with CNSs,[@b45-copd-13-1691] and this decrease was particularly significant in severe COPD compared with mild disease.[@b46-copd-13-1691] An increase in antioxidant defenses during exacerbations of COPD has also been reported.[@b25-copd-13-1691] We did not observe any significant variation in GPx1 levels in our COPD patients with prevalent airway disease or prevalent emphysema compared with CSs or CNSs. This apparent discrepancy may be due in part to the mild/moderate disease state of our patients and also to the different patient stratification (B and E groups) used in the present study.

In a study of COPD patients with increasing disease severity, the level of heparin-binding EGF was increased compared with control subjects.[@b47-copd-13-1691] In another study, comparing subjects with and without computed tomography-detected emphysema and the absence of bronchial obstruction, a significant reduction in EGF blood levels was observed in the emphysema group.[@b48-copd-13-1691] These studies are poorly comparable with each other and with our present work on account of significant differences in the COPD patients grouping; however, our observation of increased EGF blood levels in both COPD (B and E) subgroups in comparison with CNSs confirms in part Cockayne et al's study results[@b47-copd-13-1691] and supports the notion of an involvement of remodeling biomarkers in COPD, particularly in the presence of bronchial obstruction.

In line with previous studies,[@b49-copd-13-1691] we confirmed increased levels of IL-6 and IL-8 in the blood of COPD patients compared with CNSs, markers that have also been associated with progressive airflow obstruction (IL-6) and progressive emphysema (IL-6 and IL-8).[@b50-copd-13-1691]

IL-2 has been reported to be increased in COPD patients compared with controls,[@b50-copd-13-1691] but was lower in rapid decliners compared with stable COPD patients.[@b51-copd-13-1691] IL-10 in the blood of COPD patients was reported as increased in one study,[@b50-copd-13-1691] but in another study, it did not differ in COPD patients compared with controls.[@b52-copd-13-1691] IL-2 and IL-10 as well as IFN-γ and TNF-α were not reported to be associated with the progression of emphysema.[@b50-copd-13-1691] In our present study, the levels of IL-2 and IL-10 as well as IFN-γ and TNF-α in the two COPD (B and E) groups were not different with respect to CSs and CNSs, suggesting a relatively modest role for these blood biomarkers in the endotyping of our COPD groups.

In a recent study, biomass smoking COPD patients showed higher levels of Th2 cells and serum IL-4 compared with tobacco-smoking COPD patients.[@b20-copd-13-1691] In agreement, we did not find any significant difference in the blood IL-4 measurements when comparing smokers and ex-smokers from the COPD groups (B and E) to control subjects, suggesting again a minor role for this circulating cytokine in the endotyping of COPD patients.

VEGF serum levels have been variously reported as proportionally increased in COPD patients with increasing disease severity[@b53-copd-13-1691] compared with control subjects, or not changed in either stable or exacerbated COPD when the association with clinically significant outcomes was studied.[@b54-copd-13-1691] We did not find any significant changes in VEGF levels when comparing the COPD-B and COPD-E groups with CSs and CNSs, suggesting again that this remodeling biomarker does not seem to play a significant role in COPD endotyping.

In mice, cigarette smoke-induced neutrophilia is dependent on IL-1α,[@b55-copd-13-1691] and mice smoke exposure leads to increased recruitment and activation of dendritic cells.[@b56-copd-13-1691] Airway epithelial cells-derived IL-1α increased upon epithelial exposure to cigarette smoke extract.[@b57-copd-13-1691] In our study, we found the highest IL-1α blood values in smokers compared both with CNSs and with the two COPD groups (B and E), suggesting that it is the smoking habit, more than the disease state, that most influences the blood level of this cytokine.

Plasma levels of IL-1β have been reported as increased in smokers with COPD compared with CSs[@b49-copd-13-1691] or CNSs,[@b58-copd-13-1691] and sputum gene expression of IL-1β at baseline was higher in frequent exacerbators with COPD.[@b59-copd-13-1691] In bronchial and lung tissue, IL-1β immunoexpression was found to be very low, and it was similar in COPD patients and control subjects.[@b60-copd-13-1691] In our present study, we did not find significant differences in IL-1β blood levels when COPD-B and COPD-E groups were compared with CSs or CNSs. This may be due to the stable state of the disease of our patients and, in part, to the different stratification method used for grouping of our COPD patients. As a limitation of this study, we did not establish cutoff values for each one of the biomarkers studied for COPD-B and COPD-E groups, related to CNSs. This was due to the relatively low number of patients studied.

Conclusion
==========

We did not find any specific blood biomarkers that could differentiate COPD patients with prevalent airway disease from those with prevalent emphysema. Studies sampling directly the target organ by bronchial biopsy, BAL, or sputum investigations are warranted to further characterize these COPD phenotypes.
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![IL-6 is significantly increased in the blood of COPD patients with prevalent emphysema (E group), prevalent airway disease (B group), and CSs compared with CNSs (**A**); IL-8 is significantly increased in COPD-E and COPD-B compared with CNSs (**B**); EGF is significantly increased in COPD patients from COPD-E and COPD-B groups compared with CNSs (**C**); MCP-1 is significantly increased in COPD-E compared with CSs and CNSs (**D**); SOD-1 is significantly decreased in COPD-E and COPD-B compared with CNSs (**E**); F2-IsoPs is significantly increased in both COPD-B and COPD-E groups compared with CSs and CNSs, and CSs also showed higher levels compared with CNSs (**F**). Bar lines represent median values.\
**Note:** COPD-B, COPD patients with prevalent airway disease; COPD-E, COPD patients with prevalent emphysema.\
**Abbreviations:** CNS, control nonsmoker; COPD, chronic obstructive pulmonary disease; CS, control smoker; EGF, epidermal growth factor; F2-IsoPs, F2-isoprostanes; IL, interleukin; MCP, macrophage chemotactic protein; SOD, superoxide dismutase.](copd-13-1691Fig1){#f1-copd-13-1691}

![Regression analysis performed in all COPD patients (COPD-E and COPD-B groups) and CS and CNS groups showing correlations between F2-IsoPs and MCP-1 (**A**), IL-2 (**B**), IL-1β (**C**), IFN-γ (**D**), TNF-α (**E**), and SOD1 (**F**). All inflammatory molecules correlated positively and significantly with the oxidative stress marker F2-IsoPs. SOD1 correlated inversely and significantly with the oxidative stress marker F2-IsoPs.\
**Note:** COPD-B, COPD patients with prevalent airway disease; COPD-E, COPD patients with prevalent emphysema.\
**Abbreviations:** CNS, control nonsmoker; COPD, chronic obstructive pulmonary disease; CS, control smoker; F2-IsoPs, F2-isoprostanes; IFN, interferon; IL, interleukin; MCP, macrophage chemotactic protein; SOD, superoxide dismutase; TNF-α, tumor necrosis factor-α.](copd-13-1691Fig2){#f2-copd-13-1691}

![Regression analysis performed in all COPD patients (COPD-E and COPD-B groups) showing correlations between F2-IsoPs and IFN-γ (**A**), TNF-α (**B**), and IL-2 (**C**). All inflammatory molecules correlated positively and significantly with the oxidative stress marker F2-IsoPs.\
**Note:** COPD-B, COPD patients with prevalent airway disease; COPD-E, COPD patients with prevalent emphysema.\
**Abbreviations:** COPD, chronic obstructive pulmonary disease; F2-IsoPs, F2-isoprostanes; IFN, interferon; IL, interleukin; TNF, tumor necrosis factor.](copd-13-1691Fig3){#f3-copd-13-1691}

###### 

Clinical characteristics of COPD patients by phenotype and control subjects who provided blood samples

  Subjects                     Control nonsmokers   Control smokers   COPD-B                                                                                                 COPD-E
  ---------------------------- -------------------- ----------------- ------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------
  Subjects                     18                   9                 23                                                                                                     22
  M/F                          8/10                 4/5               19/4                                                                                                   20/2
  Pack/years                   --                   38.5±24           51.21±29                                                                                               40.44±31
  Ex-smokers/current smokers   --                   2/7               19/4                                                                                                   18/4
  FEV~1~ (L)                   3.34±1.2             3.2±0.8           1.19±0.52[\*](#tfn2-copd-13-1691){ref-type="table-fn"},[\#](#tfn3-copd-13-1691){ref-type="table-fn"}   1.25±0.62[\*](#tfn2-copd-13-1691){ref-type="table-fn"},[\#](#tfn3-copd-13-1691){ref-type="table-fn"}
  FEV~1~%                      116±6                102±8             55±24[\*](#tfn2-copd-13-1691){ref-type="table-fn"},[\#](#tfn3-copd-13-1691){ref-type="table-fn"}       53±22[\*](#tfn2-copd-13-1691){ref-type="table-fn"},[\#](#tfn3-copd-13-1691){ref-type="table-fn"}
  FEV~1~/FVC (%)               79±4.1               74±11             46±14[\*](#tfn2-copd-13-1691){ref-type="table-fn"},[\#](#tfn3-copd-13-1691){ref-type="table-fn"}       40±11[\*](#tfn2-copd-13-1691){ref-type="table-fn"},[\#](#tfn3-copd-13-1691){ref-type="table-fn"}
  RV (L)                       1.95±0.2             2.3±0.6           3.20±1.02[\*](#tfn2-copd-13-1691){ref-type="table-fn"},[\#](#tfn3-copd-13-1691){ref-type="table-fn"}   3.63±1.45[\*](#tfn2-copd-13-1691){ref-type="table-fn"},[\#](#tfn3-copd-13-1691){ref-type="table-fn"}
  RV%                          95.8±3               91±2              119±41[\*](#tfn2-copd-13-1691){ref-type="table-fn"},[\#](#tfn3-copd-13-1691){ref-type="table-fn"}      132±52[\*](#tfn2-copd-13-1691){ref-type="table-fn"},[\#](#tfn3-copd-13-1691){ref-type="table-fn"}
  VC (L)                       --                   --                2.56±0.68                                                                                              3.01±1.0
  VC%                          --                   --                77.7±19.5                                                                                              82.4±18.1
  DLCO (L)                     --                   --                3.75±1.72                                                                                              3.89±2.91
  DLCO%                        --                   --                50±21                                                                                                  40±16
  6MWD (m)                     --                   --                343.32±127.9                                                                                           428.20±120.8
  Exacerbations/year           --                   --                1.70±1.06                                                                                              1.29±0.73

**Notes:** Data are presented as number or mean ± SD.

*p*\<0.05 compared with control smokers;

*p*\<0.05 compared with control nonsmokers (ANOVA). COPD-B, COPD patients with prevalent airway disease; COPD-E, COPD patients with prevalent emphysema.

**Abbreviations:** 6MWD, 6-minute walking test; ANOVA, analysis of variance; COPD, chronic obstructive pulmonary disease; DLCO, diffusing capacity of the lungs for carbon monoxide; F, female; FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity; M, male; RV, residual volume; VC, vital capacity.

###### 

Quantification of molecules related to oxidative stress and cytokines in the blood

  Molecules          Control non-smokers    Control smokers                                                   COPD-B                                                                                                            COPD-E                                                                                                            Kruskal--Wallis
  ------------------ ---------------------- ----------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------- -----------------
  IL-1α (pg/mL)      0.2 (0--0.8)           0.9 (0--1.8)[\#](#tfn7-copd-13-1691){ref-type="table-fn"}         0 (0--1.3)[\*](#tfn6-copd-13-1691){ref-type="table-fn"}                                                           0.3 (0--1.1)[\*](#tfn6-copd-13-1691){ref-type="table-fn"}                                                         **0.0402**
  IL-1β (pg/mL)      0 (0--2.5)             0 (0--5.2)                                                        0.7 (0--2.7)                                                                                                      0.4 (0--2)                                                                                                        0.5877
  IL-2 (pg/mL)       1.6 (0--7)             0 (0--7.4)                                                        3.8 (0--9.6)                                                                                                      2.8 (0--7.7)                                                                                                      0.5242
  IL-4 (pg/mL)       1.3 (0--2.2)           1.8 (0--6.6)                                                      0 (0--4.5)                                                                                                        0 (0--2.9)                                                                                                        0.7530
  IL-6 (pg/mL)       0.7 (0--4.6)           1.8 (0.9--19.2)[\#](#tfn7-copd-13-1691){ref-type="table-fn"}      2.4 (0.6--620.3)[\#](#tfn7-copd-13-1691){ref-type="table-fn"}                                                     2.5 (0.9--27.9)[\#](#tfn7-copd-13-1691){ref-type="table-fn"}                                                      \<**0.0001**
  IL-8 (pg/mL)       7.1 (3--148)           8.6 (4.9--1,017)                                                  10.4 (3.9--1,207.8)[\#](#tfn7-copd-13-1691){ref-type="table-fn"}                                                  15.9 (3.9--999.4)[\#](#tfn7-copd-13-1691){ref-type="table-fn"}                                                    **0.0273**
  IL-10 (pg/mL)      0 (0--1.9)             0 (0--1.7)                                                        0 (0--2.6)                                                                                                        0 (0--2.2)                                                                                                        0.8823
  TNF-α (pg/mL)      2.7 (1.2--22.4)        2.3 (1.8--14.8)                                                   3.2 (1.4--56.6)                                                                                                   4.5 (1.6--14.4)                                                                                                   0.3500
  IFN-γ (pg/mL)      0 (0--6.5)             3.4 (0--5.5)[\#](#tfn7-copd-13-1691){ref-type="table-fn"}         0.4 (0--18.3)                                                                                                     0.5 (0--6.7)                                                                                                      0.2711
  EGF (pg/mL)        53.8 (3.5--197.2)      56.6 (11.1--163.0)                                                88.5 (8.5--203.8)[\#](#tfn7-copd-13-1691){ref-type="table-fn"}                                                    103.6 (13.1--184)[\#](#tfn7-copd-13-1691){ref-type="table-fn"}                                                    **0.0253**
  MCP-1 (pg/mL)      182.1 (130.8--333.4)   234.4 (158--440.2)                                                245.9 (109.6--452.2)                                                                                              292 (174.2--427.7)[\*](#tfn6-copd-13-1691){ref-type="table-fn"},[\#](#tfn7-copd-13-1691){ref-type="table-fn"}     **0.0187**
  VEGF (pg/mL)       132.3 (33.5--391.3)    165.6 (40.7--221.0)                                               143.0 (36.9--485.2)                                                                                               179 (52.7--857.3)                                                                                                 0.3634
  SOD1 (U/mL)        175 (132--207)         143 (138--1,333)                                                  147 (36--284)[\#](#tfn7-copd-13-1691){ref-type="table-fn"}                                                        150.50 (29--209)[\#](#tfn7-copd-13-1691){ref-type="table-fn"}                                                     **0.0388**
  GPx1 (U/L)         4,862 (4,141--6,847)   4,879 (3,136--7,216)                                              5,371 (2,230--8,364)                                                                                              5,166 (2,091--11,193)                                                                                             0.9249
  F2-IsoPs (pg/mL)   26.8 (10--39.7)        70.7 (22.6--126.8)[\#](#tfn7-copd-13-1691){ref-type="table-fn"}   142.70 (72.2--476.3)[\*](#tfn6-copd-13-1691){ref-type="table-fn"},[\#](#tfn7-copd-13-1691){ref-type="table-fn"}   111.95 (56.9--472.3)[\*](#tfn6-copd-13-1691){ref-type="table-fn"},[\#](#tfn7-copd-13-1691){ref-type="table-fn"}   \<**0.0001**

**Notes:** Data are presented as median and range. The Kruskal--Wallis test was used for multiple comparisons followed by the Mann--Whitney *U* test for comparison between groups:

*p*\<0.05, significantly different from control smokers;

*p*\<0.05, significantly different from control nonsmokers. The exact *p*-values are reported in [Table 3](#t3-copd-13-1691){ref-type="table"} and in the "Results" section. Significant values are reported in bold. COPD-B, COPD patients with prevalent airway disease; COPD-E, COPD patients with prevalent emphysema.

**Abbreviations:** EGF, epidermal growth factor; F2-IsoPs, F2-isoprostanes; GPx, glutathione peroxidase; IFN, interferon; IL, interleukin; MCP, monocyte chemotactic protein; SOD, superoxide dismutase; TNF, tumor necrosis factor; VEGF, vascular endothelial growth factor.

###### 

Statistical analysis between groups regarding the oxidative stress molecules and cytokines reported in [Table 2](#t2-copd-13-1691){ref-type="table"}

  Molecules          CNS vs CS; *p*-value   CNS vs COPD-B; *p*-value   CS vs COPD-B; *p*-value   CNS vs COPD-E; *p*-value   CS vs COPD-E; *p*-value   COPD-E vs COPD-B; *p*-value
  ------------------ ---------------------- -------------------------- ------------------------- -------------------------- ------------------------- -----------------------------
  IL-1α (pg/mL)      **0.0064**             0.9895                     **0.0119**                0.3918                     **0.0408**                0.4469
  IL-1β (pg/mL)      0.5203                 0.2026                     0.7374                    0.2479                     0.7940                    0.9367
  IL-2 (pg/mL)       0.8977                 0.1719                     0.3902                    0.4305                     0.7441                    0.4008
  IL-4 (pg/mL)       0.7188                 0.4863                     0.6298                    0.3624                     0.4083                    0.8116
  IL-6 (pg/mL)       **0.0064**             \<**0.0001**               0.3246                    \<**0.0001**               0.2963                    0.7592
  IL-8 (pg/mL)       0.1649                 **0.0292**                 0.8504                    **0.0047**                 0.3608                    0.2469
  IL-10 (pg/mL)      0.8774                 0.7726                     0.5715                    0.6440                     0.9306                    0.4606
  TNF-α (pg/mL)      0.9181                 0.3056                     0.4138                    0.0843                     0.2766                    0.5780
  IFN-γ (pg/mL)      **0.0206**             0.5457                     0.1541                    0.4465                     0.3169                    0.7420
  EGF (pg/mL)        0.3284                 **0.0459**                 0.6298                    **0.0036**                 0.2400                    0.1592
  MCP-1 (pg/mL)      0.3545                 0.1212                     0.6599                    **0.0023**                 **0.0453**                0.1526
  VEGF (pg/mL)       0.4105                 0.5457                     0.9833                    0.0819                     0.3841                    0.2859
  SOD1 (U/mL)        0.2216                 **0.0121**                 0.2758                    **0.0122**                 0.4083                    0.7164
  GPx1 (U/L)         0.5711                 0.5909                     0.9666                    0.8406                     0.6793                    0.6911
  F2-IsoPs (pg/mL)   **0.0122**             \<**0.0001**               **0.0081**                ,**0.0001**                **0.0385**                0.4652

**Notes:** CNS: n=18; CS: (n=9); COPD-B, COPD patients with prevalent airway disease; (n=23); COPD-E, COPD patients with prevalent emphysema (n=22). The *p*-values are obtained using the Mann--Whitney *U* test between groups for each of the molecules studied (reported in [Table 2](#t2-copd-13-1691){ref-type="table"}). Significant values are reported in bold.

**Abbreviations:** CNS, control nonsmoker; CS, control smoker; EGF, epidermal growth factor; F2-IsoPs, F2-isoprostanes; GPx, glutathione peroxidase; IFN, interferon; IL, interleukin; MCP, monocyte chemotactic protein; SOD, superoxide dismutase; TNF, tumor necrosis factor; VEGF, vascular endothelial growth factor.
